Jason N. Butler
Stock Analyst at Citizens
(3.85)
# 651
Out of 5,241 analysts
26
Total ratings
61.54%
Success rate
8.62%
Average return
Main Sectors:
Stocks Rated by Jason N. Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GHRS GH Research | Maintains: Market Outperform | $42 → $39 | $21.39 | +82.33% | 2 | May 15, 2026 | |
| PGEN Precigen | Maintains: Market Outperform | $9 → $11 | $4.42 | +148.87% | 3 | May 14, 2026 | |
| AVTX Avalo Therapeutics | Maintains: Market Outperform | $62 → $55 | $17.74 | +210.03% | 2 | May 14, 2026 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $19 → $20 | $9.76 | +104.92% | 1 | May 8, 2026 | |
| CRMD CorMedix | Reiterates: Market Outperform | $19 | $7.55 | +151.66% | 2 | Apr 28, 2026 | |
| NERV Minerva Neurosciences | Initiates: Market Outperform | $14 | $5.21 | +168.71% | 1 | Apr 15, 2026 | |
| NSRX Nasus Pharma | Maintains: Market Outperform | $19 → $18 | $2.89 | +522.84% | 1 | Mar 26, 2026 | |
| ESPR Esperion Therapeutics | Maintains: Market Outperform | $4 → $5 | $3.12 | +60.26% | 1 | Mar 13, 2026 | |
| ARGX argenx SE | Maintains: Market Outperform | $925 → $944 | $799.32 | +18.10% | 1 | Feb 27, 2026 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $8 → $10 | $3.58 | +179.33% | 1 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $34 → $35 | $21.40 | +63.55% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $19 | $5.29 | +259.17% | 1 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $77 → $80 | $37.07 | +115.81% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $22 | $22.32 | -1.43% | 1 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $9 → $17 | $3.34 | +408.98% | 1 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $95 → $114 | $114.53 | -0.46% | 1 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $78 | $75.85 | +2.83% | 1 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $19 → $18 | $11.01 | +63.49% | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $91 → $78 | $67.12 | +16.21% | 1 | Aug 6, 2025 |
GH Research
May 15, 2026
Maintains: Market Outperform
Price Target: $42 → $39
Current: $21.39
Upside: +82.33%
Precigen
May 14, 2026
Maintains: Market Outperform
Price Target: $9 → $11
Current: $4.42
Upside: +148.87%
Avalo Therapeutics
May 14, 2026
Maintains: Market Outperform
Price Target: $62 → $55
Current: $17.74
Upside: +210.03%
Prothena Corporation
May 8, 2026
Maintains: Market Outperform
Price Target: $19 → $20
Current: $9.76
Upside: +104.92%
CorMedix
Apr 28, 2026
Reiterates: Market Outperform
Price Target: $19
Current: $7.55
Upside: +151.66%
Minerva Neurosciences
Apr 15, 2026
Initiates: Market Outperform
Price Target: $14
Current: $5.21
Upside: +168.71%
Nasus Pharma
Mar 26, 2026
Maintains: Market Outperform
Price Target: $19 → $18
Current: $2.89
Upside: +522.84%
Esperion Therapeutics
Mar 13, 2026
Maintains: Market Outperform
Price Target: $4 → $5
Current: $3.12
Upside: +60.26%
argenx SE
Feb 27, 2026
Maintains: Market Outperform
Price Target: $925 → $944
Current: $799.32
Upside: +18.10%
Ironwood Pharmaceuticals
Feb 26, 2026
Maintains: Market Outperform
Price Target: $8 → $10
Current: $3.58
Upside: +179.33%
Feb 26, 2026
Maintains: Market Outperform
Price Target: $34 → $35
Current: $21.40
Upside: +63.55%
Nov 25, 2025
Initiates: Market Outperform
Price Target: $19
Current: $5.29
Upside: +259.17%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $77 → $80
Current: $37.07
Upside: +115.81%
Oct 29, 2025
Maintains: Market Outperform
Price Target: $18 → $22
Current: $22.32
Upside: -1.43%
Oct 29, 2025
Maintains: Market Outperform
Price Target: $9 → $17
Current: $3.34
Upside: +408.98%
Sep 25, 2025
Maintains: Market Outperform
Price Target: $95 → $114
Current: $114.53
Upside: -0.46%
Sep 2, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $75.85
Upside: +2.83%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $19 → $18
Current: $11.01
Upside: +63.49%
Aug 6, 2025
Maintains: Market Outperform
Price Target: $91 → $78
Current: $67.12
Upside: +16.21%